Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Autor: Gore L; University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA., Locatelli F; Ospedale Pediatrico Bambino Gesù, Rome, Italy.; University of Pavia, Pavia, Italy., Zugmaier G; Amgen Research (Munich), Munich, Germany. gerhardz@amgen.com., Handgretinger R; University of Tübingen, Tübingen, Germany., O'Brien MM; Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Cincinnati, OH, USA., Bader P; Division for Stem Cell Transplantation and Immunology, Department of Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt, Germany., Bhojwani D; Children's Hospital of Los Angeles, Los Angeles, CA, USA., Schlegel PG; University Children's Hospital Würzburg, Würzburg, Germany., Tuglus CA; Amgen Inc., Thousand Oaks, CA, USA., von Stackelberg A; Charité Campus Virchow, Berlin, Germany.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2018 Aug 22; Vol. 8 (9), pp. 80. Date of Electronic Publication: 2018 Aug 22.
DOI: 10.1038/s41408-018-0117-0
Databáze: MEDLINE